[Product Releases]
|
|
|
|
|
[Blog]
|
|
Most recent post
|
[News]
|
|
Can we trust docking results? Sept 2010 IBM Systems and Technology Group releases a white paper with eHiTS and Cell
Oct 2008
EPA's ToxCastTM project will use SimBioSys' eHiTS as docking engine
Nov, 2007
|
[Events]
|
| 243rd ACS
Mar 25-29, 2012 San Diego, CA
see >> more
|
|
|
|
|
|
|
|
Systematic and exhaustive software tools for structure
based rational drug design
Darryl Reid [a], Zsolt Zsoldos [a], A. P. Johnson [b]
[a]
SimBioSys Inc., 135 Queens Plate Dr, Unit 520, Toronto, Ont., M9W 6V1,
Canada.
[b] ICAMS, University of Leeds, Leeds, LS2 9JT, UK
Scientific advancements during the
past two decades have altered the way pharmaceutical research produces
new bio-active molecules. Traditional 'trial and error' drug discovery
efforts are gradually being replaced by structure based rational drug
design. A key technique is the use of methods including X-ray
crystallography and NMR for the determination of the 3-dimensional
structure of a target protein followed by various modelling techniques
for the design of small molecule ligands that could interact with the
target structure.
The first generation of the software
tools were limited to energy calculations and molecular dynamics
simulations based on simple force field models. More automated methods,
like flexible ligand docking and de novo ligand design programs have
emerged in the 90s. However, many of these software systems relied on
stochastic algorithms to perform the search, effectively performing a
computerised 'trial and error' search.
SimBioSys provides ligand design and
docking tools that are systematic, exhaustive, rely on rational rules,
heuristics and dynamic knowledge bases. The novel algorithms designed
and optimised to solve the specific problems greatly outperform the
general random methods. The presentation gives a brief overview of the
efficient algorithms behind the SPROUT (de novo ligand design) and
eHiTS (flexible ligand docking and virtual high throughput screening)
software tools. Validation test results are presented to demonstrate
the effectiveness of these tools for the solution of practical drug
design problems.
Click here to see the Presentation
|
|
|
|
|
|